<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849404</url>
  </required_header>
  <id_info>
    <org_study_id>AVT02-GL-301</org_study_id>
    <nct_id>NCT03849404</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira® in Patients With Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvotech Swiss AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alvotech Swiss AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Efficacy study of AVT02 (Alvotech Biosimilar to Adalimumab), in patients with
      moderate to severe plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the
      Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira® in Patients with
      Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS).

      This study will be conducted at about 40 study centers in central and eastern European
      countries. A contract research organization, will oversee operational aspects of this study
      on behalf of Alvotech Swiss AG (Alvotech), the Sponsor of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Actual">July 20, 2020</completion_date>
  <primary_completion_date type="Actual">December 23, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a double blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Percent (%) change in Psoriasis Area and Severity Index (PASI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Percent improvement in PASI from BL to Week 8, 12, 24, 32, 42, and 50</time_frame>
    <description>Percent (%) change in Psoriasis Area and Severity Index (PASI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">413</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>AVT02 100mg/mL (Adalimumab Biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to AVT02 on 1: 1 basis from the dosing day of Day 1 until week 48</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-Humira 100mg/mL (Adalimumab Originator)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to EU-Humira on 1: 1 basis from the dosing day of Day 1 until week 48</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48</description>
    <arm_group_label>AVT02 100mg/mL (Adalimumab Biosimilar)</arm_group_label>
    <arm_group_label>EU-Humira 100mg/mL (Adalimumab Originator)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with moderate-to-severe chronic plaque psoriasis who has involved body surface
             area (BSA) ≥ 10% (Palm Method), ≥ 12 on the PASI, and static Physicians Global
             Assessments (sPGA) ≥ 3 (moderate) at Screening and at BL.

          -  Patient has had stable psoriatic disease for at least 2 months (ie, without
             significant changes as defined by the Investigator or designee).

          -  Patient is a candidate for systemic therapy and the patient has a previous failure,
             inadequate response, intolerance, or contraindication to at least 1 systemic
             antipsoriatic therapy including, but not limited to, methotrexate, cyclosporine,
             psoralen plus ultraviolet light A (PUVA), and ultraviolet light B (UVB).

        Exclusion Criteria:

          -  Patient has prior use of 2 or more biologics for treatment of PsO.

          -  Patient diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,
             medication-induced psoriasis, other skin conditions (eg, eczema), or other systemic
             autoimmune disorder inflammatory disease at the time of the Screening visit that would
             interfere with evaluations of the effect of the study drug on psoriasis.

          -  Patient has prior use of any of the following medications within specified time
             periods or will require use during the study:

               1. Topical medications within 2 weeks of BL (Week 1).

               2. PUVA phototherapy and/or UVB phototherapy within 4 weeks prior to the BL Visit.

               3. Nonbiologic psoriasis systemic therapies (eg, cyclosporine, methotrexate, and
                  acitretin) within 4 weeks prior to the BL Visit.

               4. Any prior or concomitant or biosimilar adalimumab therapy, either approved or
                  investigational.

               5. Any systemic steroid in the 4 weeks prior to BL.

        Note: Only key inclusion/exclusion criteria mentioned here. Patients will be screened and
        randomized per the list in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Feldman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Estonia Medical Centre Foundation, Dermatovenerology Centre</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innomedica OU</name>
      <address>
        <city>Tallin</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OU Vahlberg &amp; Pild</name>
      <address>
        <city>Tallin</city>
        <zip>10134</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital, Dermatology Clinic</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aleksandre Aladashvili Clinic LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first University Clinic of Tbilisi State Medical University</name>
      <address>
        <city>Tbilisi</city>
        <zip>0141</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research National Center of Dermatology and Venereology LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Institute LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Abuladze Georgian-Italian Clinic LTD</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk, Nowak Spółka Jawna</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych PI-House Sp. Z o.o.</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddział w Gdańsku</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Med Kraków Sp. Z o.o.</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ &quot;Nasz Lekarz&quot; Sławomir Jeka, Praktyka Grupowa Lekarzy Rodzinnych z Przychodnią Specjalistyczną</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o.Oddział w Warszawie</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermMedica Sp. z o.o.</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddział we Wrocławiu</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczna ALL-MED</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhya Regional Dermatology and Venereology Clinical Dispensary</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Poland</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

